http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Article/list/43931 Latest news on age related macular degeneration (AMD) research and therapies. 2013-05-21T13:14:55Z http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Increased-intake-of-carotenoids-and-fish-oil-doesn/ArticleStandard/Article/detail/813254?contextCategoryId=43931&ref=25 Increased oral supplementation of carotenoids (lutein and zeaxanthin) and omega-3 fatty acids, found in fish oil, does not reduce the risk of AMD progression further to the original AREDS formulation, claims the latest results of the Age-Related Eye Disease Study (AREDS2). 2013-05-20T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/202013/813254null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Laser-confocal-imaging-useful-for-AMD/ArticleStandard/Article/detail/807451?contextCategoryId=43931&ref=25 Scanning laser ophthalmoscopy with a lateral confocal aperture could highlight subclinical drusen and aid in the progression of monitoring in AMD patients, claims the latest paper in the British Journal of Ophthalmology. 2013-03-14T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/102013/807451null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Macular-translocation-is-still-effective-after-fiv/ArticleStandard/Article/detail/779355?contextCategoryId=43931&ref=25 It is possible for AMD patients to maintain BCVA for fives years after macular translocation surgery.. 2012-07-03T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/262012/779355null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Cases-of-peripheral-yellow-corneal-rings-of-AMD-re/ArticleStandard/Article/detail/775584?contextCategoryId=43931&ref=25 Peripheral yellow corneal rings are more common in age-related macular degeneration (AMD). 2012-06-07T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/222012/775584null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Implantable-telescope-finally-gets-FDA-approval/ArticleStandard/Article/detail/678352?contextCategoryId=43931&ref=25 VisionCare&#;s implantable telescope for end-stage AMD has finally been given FDA approval. The device, discussed in depth in Ophthalmology Times Europe July 2007, was given CE approval three years ago but has subsequently been undergoing rigorous clinical trials in the United States. 2010-07-09T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/282010/678352null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/IRay-stereotactic-radiotherapy-system-gets-Europea/ArticleStandard/Article/detail/664827?contextCategoryId=43931&ref=25 Oraya Therapeutics has been granted the CE mark for its IRay system, which its researchers say can deliver low-energy X-rays to treat wet AMD. 2010-04-14T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/162010/664827null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+Clinicals/First-ever-sham-controlled-study-of-radiation-ther/ArticleStandard/Article/detail/651120?contextCategoryId=43931&ref=25 )? Oraya Therapeutics, Inc., announced today that enrollment is now underway for the first ever masked and sham-controlled study to demonstrate the efficacy and safety of radiation therapy for the treatment of wet age-related macular degeneration (AMD). The groundbreaking clinical trial is being conducted at seven European sites, and will include a minimum of 150 patients, with approximately one third of those receiving a sham exposure and the remainder receiving radiation dosing of either 16 or 24 Gray (GY). 2010-01-13T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/032010/651120null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Cancer-drug-no-different-in-effectiveness-as-gold-/ArticleStandard/Article/detail/633253?contextCategoryId=43931&ref=25 Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). 2009-10-14T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/422009/633253null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Early-AMD-associated-with-coronary-heart-disease/ArticleStandard/Article/detail/612229?contextCategoryId=43931&ref=25 The results of a study published in the July issue of Ophthalmology has discovered that people in the early stages of age-related macular degeneration (AMD) are at a higher risk of developing coronary heart disease (CHD), offering further support to the theory that AMD is associated with underlying systemic vascular disease. 2009-07-22T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/302009/612229null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/AMD-prediction-a-step-closer-using-nature-or-nutur/ArticleStandard/Article/detail/610488?contextCategoryId=43931&ref=25 Prevalence and incidence of advanced AMD can be catergorized as 'nature' or 'nurture' using a prediction model, based on genetic, environmental and demographic variables. 2009-07-15T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/292009/610488null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/AMD-biological-marker-discovered/ArticleStandard/Article/detail/603606?contextCategoryId=43931&ref=25 A biological marker for neovascular age-related macular degeneration (AMD) has been discovered by a team of researchers from the University of Kentucky. 2009-06-17T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/252009/603606null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Question-mark-over-Novartis-combination-therapy/ArticleStandard/Article/detail/603602?contextCategoryId=43931&ref=25 The twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study investigating the efficacy and safety of combining Visudyne (Novartis Pharma AG) and Lucentis (Novartis Pharma AG, Genentech Inc.) have been released and so far are showing no significant differences. 2009-06-17T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/252009/603602null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Dr-Ambati-wins-2010-ARVO-award/ArticleStandard/Article/detail/603598?contextCategoryId=43931&ref=25 Dr Jayakrishna Ambati, professor and vice chairman of Ophthalmology and Visual Sciences at the University of Kentucky, has been chosen to receive the 2010 Cogan Award from The Association for Research in Vision and Opthalmology (ARVO). 2009-06-17T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/252009/603598null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Visudyne-evaluation-indicates-positive-results/ArticleStandard/Article/detail/602107?contextCategoryId=43931&ref=25 Positive twelve-month primary analysis results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with wet age-related macular degeneration (wet AMD) have been announced by QLT Inc. 2009-06-10T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/242009/602107null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Vitamin-supplement-to-afford-long-term-benefit-for/ArticleStandard/Article/detail/596107?contextCategoryId=43931&ref=25 Patients suffering from AMD have experienced long-term benefits from using the Macular Health vitamin supplement following the second phase of the Multifocal Electroretinogram (MERG) study at the Callahan Eye Foundation Hospital at the University of Alabama Birmingham (US). 2009-05-06T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/182009/596107null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Study-of-Anti-PDGF-and-Anti-VEGF-therapy-shows-sig/ArticleStandard/Article/detail/596571?contextCategoryId=43931&ref=25 Ophthotech Corp. has announced positive results of a phase I clinical study evaluating E10030, its novel anti-platelet derived growth factor (anti-PDGF) in conjunction with an anti-vascular endothelial growth factor (anti-VEGF), to treat wet age-related macular degeneration (wet AMD). 2009-05-06T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/192009/596571null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Fenretinide-Phase-II-trials-results-imminent/ArticleStandard/Article/detail/594146?contextCategoryId=43931&ref=25 Interim analysis of Phase II trials for fenretinide and its use in the treatment of geographic atrophy (GA) are looking positive, according to Sirion Therapeutics, Inc. 2009-04-22T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/172009/594146null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/FDA-approves-implant-telescope-for-end-stage-AMD/ArticleStandard/Article/detail/591770?contextCategoryId=43931&ref=25 The premarket application for VisionCare Ophthalmic Technologies Inc's implantable telescope for end-stage AMD has been approved, with conditions, by the FDA in the US. 2009-04-08T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/152009/591770null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/New-wet-AMD-treatment-a-step-closer/ArticleStandard/Article/detail/588583?contextCategoryId=43931&ref=25 The CABERNET (CNV Secondary to AMD Treated with Beta RadiatioN Epiretinal Therapy) clinical trial is pivotal to establishing the safety and effectiveness of a beta radiation based focal epimacular brachytherapy device. Its development in bringing a paradigm shift in the way retina specialists treat wet AMD patients moved a step closer as Neovista Inc. secured more than $18 million in its Series D private venture funding round. 2009-03-25T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/132009/588583null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Red-meat-consumption-associated-with-early-AMD/ArticleStandard/Article/detail/588588?contextCategoryId=43931&ref=25 According to Eye Research Australia researchers at the University of Melbourne, a high intake of fresh and processed red meat is positively associated with early AMD, the leading cause of blindness among older people. Diet has often been postulated to alter the risk of AMD. 2009-03-25T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/132009/588588null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Nutritional-supplement-market-growing/ArticleStandard/Article/detail/587354?contextCategoryId=43931&ref=25 The eyecare nutritional supplement market is worth $43.4 million and is projected to grow to $87.4 million within five years, according to research by Frost & Sullivan. 2009-03-18T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/122009/587354null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Online-resource-for-AMD/ArticleStandard/Article/detail/583736?contextCategoryId=43931&ref=25 Ocular nutraceutical company, EyeScience Labs, LLC, has launched www.EyeScience.com that aims to meet the need for comprehensive information and education on age-related macular degeneration (AMD) in a watch-and-learn video format. 2009-03-04T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/092009/583736null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Raising-AMD-awareness/ArticleStandard/Article/detail/582460?contextCategoryId=43931&ref=25 Novartis Pharmaceuticals UK Ltd, supported by the Royal National Institute of Blind People (RNIB), has launched "Be AMD Aware", a campaign to raise awareness of the risk factors for and symptoms of age-related macular generation (AMD) among those aged 55 and over in the UK. 2009-02-25T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082009/582460null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Antioxidants-preserve-vision-in-retina-disease/ArticleStandard/Article/detail/581663?contextCategoryId=43931&ref=25 Consumption of antioxidants may enable retinal degeneration patients to preserve vision even while vascular abnormalities continue to exist, concluded a study published online ahead of print by the Journal of Clinical Investigation. 2009-02-18T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082009/581663null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Phaco-does-not-boost-AMD-progression/ArticleStandard/Article/detail/580357?contextCategoryId=43931&ref=25 No clear link between cataract surgery and progressive age-related macular degeneration (AMD) could be established by a study published in the February issue of Ophthalmology. 2009-02-11T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/072009/580357null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Lucentis-approved-in-Japan/ArticleStandard/Article/detail/577235?contextCategoryId=43931&ref=25 Lucentis (ranibizumab; Novartis) has been approved for the treatment of wet age-related macular degeneration (AMD) in Japan, Novartis has announced. 2009-01-28T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/042009/577235null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/AMD-drug-collaboration/ArticleStandard/Article/detail/576015?contextCategoryId=43931&ref=25 MacuCLEAR and Mystic Pharmaceuticals are to collaborate on MacuCLEAR's upcoming Phase I/II trials of MC 1101 for the treatment and prevention of progression of dry age-related macular degeneration (AMD). 2009-01-21T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/042009/576015null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Iluvien-investigated-for-dry-AMD/ArticleStandard/Article/detail/571653?contextCategoryId=43931&ref=25 A pilot study using Iluvien (an intravitreal insert delivering fluocinolone acetonide) to treat geographic atrophy secondary to age-related macular degeneration (AMD) has begun enrolling patients, according to a statement from Alimera Sciences Inc, the developer of Iluvien. 2008-12-17T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/512008/571653null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Compassionate-use-of-radiation-treatment-for-AMD-a/ArticleStandard/Article/detail/571656?contextCategoryId=43931&ref=25 NeoVista's epiretinal brachytherapy has been granted a compassionate waiver by the FDA to treat advanced wet age-related macular degeneration (AMD) in a patient who was not eligible for inclusion in NeoVista's current trials of the product. 2008-12-17T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/512008/571656null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Same-day-administration-of-AMD-drugs/ArticleStandard/Article/detail/568597?contextCategoryId=43931&ref=25 It is possible to administer verteporfin and ranibizumab on the same day without adverse events, according to study results published in the December issue of the British Journal of Ophthalmology. 2008-12-03T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482008/568597null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Macugen-three-year-safety/ArticleStandard/Article/detail/568598?contextCategoryId=43931&ref=25 Pegaptanib sodium therapy is safe in patients with neovascular age-related macular degeneration (NV-AMD) up to three years, according to study results published in the December issue of the British Journal of Ophthalmology. 2008-12-03T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482008/568598null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Avastin-optimum-dosing-schedule-defined/ArticleStandard/Article/detail/568595?contextCategoryId=43931&ref=25 When using bevacizumab to treat choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), a loading dose (LD) of bevacizumab is more effective than an as-needed (PRN) dosing schedule, according to study results published in the December issue of the British Journal of Ophthalmology. 2008-12-03T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482008/568595null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Antioxidant-dry-AMD-eye-drop/ArticleStandard/Article/detail/568673?contextCategoryId=43931&ref=25 An antioxidant eye drop (OT-551, Othera) is being investigated to treat geographic atrophy in dry age-related macular degeneration (AMD). 2008-12-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/492008/568673null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Night-vision-and-AMD/ArticleStandard/Article/detail/568703?contextCategoryId=43931&ref=25 Problems with night vision correlate to an increase in the risk of symptoms of both the wet and dry forms of age-related macular degeneration (AMD), according to study results published in the November issue of Ophthalmology. 2008-12-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/492008/568703null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Welsh-AMD-network-established/ArticleStandard/Article/detail/567566?contextCategoryId=43931&ref=25 An ophthalmology network, aiming to prevent loss of vision across the country, has been established in Wales. 2008-11-26T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/472008/567566null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Potentia-unveils-AMD-drug-results/ArticleStandard/Article/detail/565200?contextCategoryId=43931&ref=25 A Phase I trial of POT-4, a complement inhibitor in development for the treatment of age-related macular degeneration (AMD), have demonstrated that the agent is safe and well tolerated. The results were presented by Potentia Pharmaceuticals during the Retina Subspecialty Day at the meeting of the American Academy of Ophthalmology. 2008-11-17T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/462008/565200null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/AMD-gene-discovered/ArticleStandard/Article/detail/560962?contextCategoryId=43931&ref=25 The SERPING1 gene code influences the likelihood of developing age-related macular degeneration (AMD), according to study results published online ahead of print by The Lancet. 2008-11-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/432008/560962null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/New-AMD-drug-enters-trials/ArticleStandard/Article/detail/560701?contextCategoryId=43931&ref=25 iSONEP (sonepcizumab), Lpath, Inc's drug candidate for treating age-related macular degeneration (AMD), has been administered to the first patients in its Phase I trial. 2008-10-27T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/432008/560701null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Individual-VA-varies-in-AMD-patients/ArticleStandard/Article/detail/557148?contextCategoryId=43931&ref=25 Visual acuity (VA) in age-related macular degeneration (AMD) patients may vary significantly between measurement sessions, according to study results published in the October 2008 issue of Investigative Ophthalmology & Visual Sciences. 2008-10-13T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/412008/557148null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Colourful-food-increases-vision-for-AMD-patients/ArticleStandard/Article/detail/555560?contextCategoryId=43931&ref=25 Consuming dark-coloured fruits and vegetables increases the levels of macular pigment (MP) and is associated with improved vision in age-related macular degeneration (AMD) sufferers, according to study results published in the New Straits Times Online on September 22. 2008-10-06T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/402008/555560null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Dry-AMD-gene-found/ArticleStandard/Article/detail/552303?contextCategoryId=43931&ref=25 The discovery of the first gene known to be associated with dry age-related macular degeneration (AMD) has significant implications for the prevention and treatment of the condition, according to a study published in the October 2, 2008 issue of the New England Journal of Medicine. 2008-10-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/392008/552303null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/RP-amp-dry-AMD-candidate-on-the-fast-track/ArticleStandard/Article/detail/547692?contextCategoryId=43931&ref=25 Neurotech Pharmaceuticals has been granted Fast Track designations by the FDA for NT-501 for the treatment of visual loss in retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD). 2008-09-08T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/362008/547692null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Antioxidants-join-the-fight-against-AMD/ArticleStandard/Article/detail/547690?contextCategoryId=43931&ref=25 According to a report published in the September 5th issue of the Journal of Biological Chemistry, two processes in the retina, which in combination contribute to age-related macular degeneration (AMD), can be disrupted by antioxidants. 2008-09-08T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/362008/547690null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Oily-fish-cut-AMD-risk-by-50/ArticleStandard/Article/detail/543011?contextCategoryId=43931&ref=25 Eating oily fish just once a week may cut the risk of developing wet age-related macular degeneration (AMD) by half, according to results of the EUREYE study, published in the August 2008 issue of the American Journal of Clinical Nutrition. 2008-09-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/342008/543011null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Alcon-drops-AMD-candidate/ArticleStandard/Article/detail/530395?contextCategoryId=43931&ref=25 Following disappointing clinical trial results, Alcon has discontinued its plans to develop anecortave acetate for the prevention of choroidal neovascularization secondary to age-related macular degeneration (AMD). 2008-07-21T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/292008/530395null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Wet-AMD-sufferers-unaware-of-pre-existing-AMD/ArticleStandard/Article/detail/526460?contextCategoryId=43931&ref=25 Current screening of patients with age-related macular degeneration (AMD) does not sufficiently identify those patients most at risk of wet AMD and hence is unable to prevent its development, according to a report published in the June 2008 issue of Eye. 2008-07-14T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/262008/526460null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+clinical/Protecting-against-AMD/ArticleStandard/Article/detail/533571?contextCategoryId=43931&ref=25 Dr John Nolan discusses the crucial role of the macular carotenoids in the prevention of this blinding disease. 2008-07-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/322008/533571/Old-man-eye_flash.jpg XML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Needle-free-retina-drug-delivery-device-launched/ArticleStandard/Article/detail/525100?contextCategoryId=43931&ref=25 A revolutionary, needle-free technology that has been designed to deliver retina therapies non-invasively, to the back of the eye, has been launched. 2008-06-25T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/252008/525100null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+clinical/Combination-therapies-for-AMD-pose-an-intriguing-a/ArticleStandard/Article/detail/523777?contextCategoryId=43931&ref=25 The Verteporfin Intravitreal Triamcinolone Acetonide Study (VERITAS) of intravitreal triamcinolone acetonide (Kenalog, Bristol-Myers Squibb) or pegaptanib (Macugen, Pfizer) in combination with photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis Pharmaceuticals) was underpowered to reach definitive conclusions about the therapies. 2008-06-18T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/242008/523777null XML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Fish-helps-prevent-AMD/ArticleStandard/Article/detail/523741?contextCategoryId=43931&ref=25 Eating a diet rich in omega-3 fatty acids seems to correlate with a low incidence of age-related macular degeneration (AMD), according to a study published in the June 2008 issue of the Archives of Ophthalmology. 2008-06-18T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/242008/523741null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Model-predicts-advanced-AMD-development/ArticleStandard/Article/detail/523780?contextCategoryId=43931&ref=25 A new model can predict the percentage of people who will develop advanced age-related macular degeneration (AMD) at various ages. The model, which is based on well-established risk factors for the disease such as age, smoking, and genetics, considers high-risk, intermediate-risk, and low-risk genotypes. Genotypes are more predictive of the risk of developing advanced AMD than is age. 2008-06-18T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/242008/523780null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Dry-AMD-trial-doses-first-patient/ArticleStandard/Article/detail/522153?contextCategoryId=43931&ref=25 US firm Acucela Inc. has dosed the first patient in the Phase I trial of its lead candidate, ACU-02, an oral compound which is in development for dry age-related macular degeneration (AMD). 2008-06-11T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/232008/522153null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Untreated-AMD-worsens-vision/ArticleStandard/Article/detail/520102?contextCategoryId=43931&ref=25 Delaying treatment in patients with subfoveal neovascular age-related macular degeneration (wet AMD) correlates to progressive and substantial loss of visual acuity (VA), according to a report published online ahead of print by Eye. 2008-06-04T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/222008/520102null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina/OPTTX-system-offers-hope-to-some-wet-AMD-sufferers/ArticleStandard/Article/detail/519676?contextCategoryId=43931&ref=25 The OPTTX System (Novadaq Technologies) stabilizes or improves vision at one year in patients with wet age-related macular degeneration (AMD), many of who have failed previous therapies and have no other treatment alternatives, according to Professor Giovanni Staurenghi of Sacco Hospital, University of Milan, Italy, reporting at this year?s EURETINA congress in Vienna, Austria. 2008-06-04T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/222008/519676null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Nanotherapy-for-AMD/ArticleStandard/Article/detail/517438?contextCategoryId=43931&ref=25 The use of green gold nanoparticles may have a place in the therapy of cancer and ophthalmic diseases, according to a study presented at this year's meeting of the Association for Research in Vision & Ophthalmology (ARVO). 2008-05-21T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/202008/517438null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Xibrom-useful-adjuvant-to-Lucentis-in-treatment-of/ArticleStandard/Article/detail/514778?contextCategoryId=43931&ref=25 Xibrom (bromfenac 0.09 mg ophthalmic solution; ISTA Pharmaceuticals) significantly improves visual acuity outcomes and lowers retreatment rates when administered as an adjuvant to Lucentis (ranibizumab; Novartis) therapy in neovascular age-related macular degeneration (AMD) patients, when compared with Lucentis monotherapy, according to a poster presented at this year's Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). 2008-05-07T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/192008/514778null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+clinical/Can-statins-treat-AMD-effectively/ArticleStandard/Article/detail/513728?contextCategoryId=43931&ref=25 At present, there is no effective early-stage treatment for AMD or for arresting its progression in the early phases. 2008-05-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/182008/513728null XML http://www.oteurope.com/ophthalmologytimeseurope/Retina+clinical/Fewer-retreatments-with-combination-AMD-therapy/ArticleStandard/Article/detail/513724?contextCategoryId=43931&ref=25 Providing patients with renewed hope and the chance of halting and maybe even reversing vision loss, the launch of this anti-VEGF therapy has signalled a permanent change in the way this debilitating disorder is treated worldwide. 2008-05-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/182008/513724null XML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/AMD-linked-to-increased-incidence-of-death-from-st/ArticleStandard/Article/detail/509577?contextCategoryId=43931&ref=25 Age-related macular degeneration (AMD) may be a useful indicator for predicting death from stroke or cardiovascular disease, according to a study published online ahead of print by the British Journal of Ophthalmology. 2008-04-16T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/152008/509577null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Office-safer-than-the-operating-theatre-for-intrav/ArticleStandard/Article/detail/504302?contextCategoryId=43931&ref=25 The incidence of endophthalmitis following injections of anti-VEGF drugs is lower when the injections are given in an office setting than the rates reported from clinical trials, which require a more extensive pre-injection regimen. 2008-03-26T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/122008/504302null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/New-protein-offers-hope-to-AMD-sufferers/ArticleStandard/Article/detail/504305?contextCategoryId=43931&ref=25 A protein, called Robo4, has been identified which appears to play an important role in the development of stable, working blood vessels. 2008-03-26T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/122008/504305null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Fewer-Lucentis-injections-with-new-regimen/ArticleStandard/Article/detail/501208?contextCategoryId=43931&ref=25 Preliminary results of a study using the NSAID Xibrom (bromfenac ophthalmic solution 0.09%; ISTA Pharmaceuticals) therapy in combination with Lucentis (ranibizumab; Novartis) in patients with wet age-related macular degeneration (AMD), suggests that it may result in fewer injections being required. 2008-03-12T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/102008/501208null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Sirolimus-safe-and-well-tolerated-in-wet-AMD-patie/ArticleStandard/Article/detail/498805?contextCategoryId=43931&ref=25 MacuSight has announced positive preliminary data from the Phase I study of its lead product candidate for wet age-related macular degeneration (AMD), sirolimus. 2008-03-05T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/092008/498805null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/Side-effects-of-Avastin-are-minimal/ArticleStandard/Article/detail/493609?contextCategoryId=43931&ref=25 The side effects and complications associated with intravitreal bevacizumab (Avastin) are minimal and can be prevented, in most cases, by careful injection and good patient selection. 2008-02-27T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082008/493609null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/High-affinity-VEGF-binder-could-be-CNV-treatment-o/ArticleStandard/Article/detail/487858?contextCategoryId=43931&ref=25 A single intravitreal injection of the fusion protein KH902 can effectively inhibit leakage and growth of choroidal neovascularization in rhesus monkeys. 2008-02-06T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/052008/487858null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Genentech-backs-down-under-pressure-from-US-ophtha/ArticleStandard/Article/detail/489240?contextCategoryId=43931&ref=25 Genentech has resolved its dispute with American ophthalmologists over the off-label use of its anti-VEGF drug Avastin, and will now allow physicians to purchase the drug directly from authorized wholesale distributors. 2008-02-05T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/062008/489240null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+clinical/Simplified-severity-scale-may-be-predictive-of-vis/ArticleStandard/Article/detail/503064?contextCategoryId=43931&ref=25 The Simplified Age-Related Eye Disease Study (AREDS) Age-Related Macular Degeneration (AMD) Severity Scale has been shown to be predictive of vision loss. 2008-02-01T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/112008/503064/scaleup_flash.jpg XML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Triple-therapy-viable-option-for-anti-VEGF-non-res/ArticleStandard/Article/detail/487836?contextCategoryId=43931&ref=25 Triple therapy for age-related macular degeneration (AMD) can stabilize vision and reduce the re-treatment rate in patients who do not respond to initial anti-VEGF therapy. 2008-01-30T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/052008/487836null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Angiogenesis-pioneer-dies/ArticleStandard/Article/detail/485382?contextCategoryId=43931&ref=25 Judah Folkman, MD, the pioneer of angiogenesis research, died on January 15th 2008. 2008-01-25T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/032008/485382null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+news/AAO-has-good-news-for-its-members/ArticleStandard/Article/detail/484398?contextCategoryId=43931&ref=25 The American Academy of Ophthalmology and the American Society of Retina Specialists (ASRS) are pleased to report that a solution has been found that addresses Genentech's decision to no longer allow compounding pharmacies to purchase Avastin (bevacizumab) directly from authorized wholesale distributors. 2008-01-15T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/032008/484398null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Ophthotech-gains-commericial-rights-to-AMD-antibod/ArticleStandard/Article/detail/484146?contextCategoryId=43931&ref=25 Ophthotech, Biogen and PDL BioPharma have entered into an exclusive worldwide licensing agreement for an anti-angiogenesis antibody to treat age-related macular degeneration. 2008-01-14T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/032008/484146null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Endostatin-prevents-abnormal-blood-vessel-growth/ArticleStandard/Article/detail/483021?contextCategoryId=43931&ref=25 A research report published in the December issue of the FASEB Journal, describes a new experimental drug, endostatin, which can significantly reduce or eliminate abnormal blood vessel growth within the eye. 2008-01-09T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/022008/483021null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/A-NICE-turn-of-events-earlier-decision-to-limit-ac/ArticleStandard/Article/detail/479734?contextCategoryId=43931&ref=25 A controversial decision by NICE to limit the use of the anti-VEGF drug Lucentis in treating patients with wet AMD, is being reconsidered. 2007-12-17T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/512007/479734/Uturn_flash.jpg HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Open-letter-from-Genentech/ArticleStandard/Article/detail/477096?contextCategoryId=43931&ref=25 Click here to read Genentech's open letter to ophthalmologists, outlining its reason for imposing restrictions on the use of Avastin. 2007-12-04T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/492007/477096/Letter_flash.jpg HTML http://www.oteurope.com/ophthalmologytimeseurope/Pipeline+features/AMD-therapies-in-Phase-I/ArticleStandard/Article/detail/476062?contextCategoryId=43931&ref=25 Have a look at the AMD therapies taking the first step along the path to approval. 2007-11-29T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482007/476062/P1-flash_flash.jpg HTML http://www.oteurope.com/ophthalmologytimeseurope/Pipeline+features/AMD-therapies-in-Phase-II/ArticleStandard/Article/detail/476058?contextCategoryId=43931&ref=25 What therapies have made it to Phase II clinical trials? 2007-11-29T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482007/476058/P2-flash_flash.jpg HTML http://www.oteurope.com/ophthalmologytimeseurope/Pipeline+features/AMD-therapies-in-Phase-III/ArticleStandard/Article/detail/476056?contextCategoryId=43931&ref=25 Take a look at the therapies that have reached Phase III clinical testing. 2007-11-29T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482007/476056/P3-flash_flash.jpg HTML http://www.oteurope.com/ophthalmologytimeseurope/Pipeline+features/Marketed-AMD-therapies/ArticleStandard/Article/detail/475630?contextCategoryId=43931&ref=25 Take a look at the therapies that have already reached the market. 2007-11-28T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482007/475630/Market-flash_flash.jpg HTML http://www.oteurope.com/ophthalmologytimeseurope/Pipeline+features/Off-label-AMD-therapies/ArticleStandard/Article/detail/475697?contextCategoryId=43931&ref=25 What are doctors using off-label to treat their AMD patients? 2007-11-28T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482007/475697/Off-flash_flash.jpg HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Neurotech-completes-enrolment-for-dry-AMD-amp-RP-t/ArticleStandard/Article/detail/474760?contextCategoryId=43931&ref=25 Neurotech Pharmaceuticals has completed enrolment for three ongoing clinical studies evaluating NT-501 as a treatment for retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD). 2007-11-26T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482007/474760null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/AMD-diagnostic-based-on-genetic-variations-license/ArticleStandard/Article/detail/474754?contextCategoryId=43931&ref=25 Ophtherion has licensed the worldwide rights to develop diagnostic products for age-related macular degeneration (AMD) associated with specific variations in genes on Chromosome 10, from the University of Pittsburgh, USA. 2007-11-26T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482007/474754null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/AMD-supplements-increase-smokers-risk-of-cancer/ArticleStandard/Article/detail/473996?contextCategoryId=43931&ref=25 Smokers with age-related macular degeneration (AMD) should not be taking the age-related eye disease study (AREDS) formulation of vitamins and antioxidants, as it puts them at an increased risk of developing lung cancer, according to a presentation given at the Retina Subspecialty Day of this year's AAO congress in New Orleans, US. 2007-11-20T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/472007/473996null HTML http://www.oteurope.com/ophthalmologytimeseurope/Ophthalmology+research+news/Concomitant-therapy-of-epiretinal-radiation-bevaci/ArticleStandard/Article/detail/475074?contextCategoryId=43931&ref=25 Concomitant delivery of focal radiotherapy and bevacizumab (Avastin, Genentech) showed promise in a small multicenter feasibility study of patients with neovascular age-related macular degeneration. 2007-11-12T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482007/475074null HTML http://www.oteurope.com/ophthalmologytimeseurope/Ophthalmology+research+news/VEGF-Trap-promising-for-neovascular-AMD/ArticleStandard/Article/detail/474791?contextCategoryId=43931&ref=25 VEGF Trap (Regeneron Pharmaceuticals) has been seen in two studies (CLEAR-IT AMD 1 and CLEAR-IT AMD 2) to be safe, bioefficacious, and tolerated in the eyes of patients with neovascular age-related macular degeneration. 2007-11-09T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482007/474791null HTML http://www.oteurope.com/ophthalmologytimeseurope/Ophthalmology+research+news/OCT-guided-treatment-of-neovascular-AMD-preserves-/ArticleStandard/Article/detail/474790?contextCategoryId=43931&ref=25 The results of the PrONTO Study, an exploratory open-label trial, indicated that intravitreal injection of ranibizumab (Lucentis, Genentech) produces rapid improvements in visual acuity and findings on optical coherence tomography (OCT) in patients treated for neovascular age-related macular degeneration. 2007-11-09T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482007/474790null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+clinical/AMD-innovation-in-the-fast-lane/ArticleStandard/Article/detail/470797?contextCategoryId=43931&ref=25 The field of age-related macular degeneration (AMD) research continues to experience exciting and fascinating times, with the recent launches of new therapeutics and several others on the horizon giving hope to more patients than ever before. Coupled with advances in imaging and diagnostic technology, retina specialists now face AMD with fresh optimism — treatments and technologies are available that will help them to delay or maybe even halt disease progression in their patients. 2007-11-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/452007/470797null XML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/RETAANE-what-does-the-future-hold/ArticleStandard/Article/detail/469729?contextCategoryId=43931&ref=25 Alcon has received an approvable letter from the FDA for RETAANE 15 mg (anecortave acetate depot suspension) for the treatment of wet age-related macular degeneration (AMD), however the letter advised that an additional clinical study would be required before approval is given. 2007-11-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/442007/469729null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Genentech-denies-US-specialists-of-Avastin/ArticleStandard/Article/detail/469720?contextCategoryId=43931&ref=25 Genentech is seeking to restrict the use of its anti-VEGF drug Avastin by ophthalmologists in the US. 2007-11-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/442007/469720null HTML http://www.oteurope.com/ophthalmologytimeseurope/Retina+clinical/Daily-supplements-could-reduce-AMD-risk/ArticleStandard/Article/detail/470800?contextCategoryId=43931&ref=25 Randomized data from a large cohort of women with cardiovascular disease or at a high risk of it indicate that seven years of daily supplementation with folic acid, vitamin B6, and vitamin B12 may reduce the risk of age-related macular degeneration (AMD), according to William G. Christen, ScD, PhD. 2007-11-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/452007/470800/Pills_flash.jpg XML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/AMD-progression-linked-to-carbohydrates/ArticleStandard/Article/detail/465887?contextCategoryId=43931&ref=25 Patients at risk of advanced age-related macular degeneration (AMD) progression may benefit from consuming a smaller amount of refined carbohydrates. 2007-10-23T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/422007/465887null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/C-reactive-protein-level-indicates-AMD-risk/ArticleStandard/Article/detail/465888?contextCategoryId=43931&ref=25 People with high blood levels of C-reactive protein may be at higher risk of developing age-related macular degeneration. 2007-10-23T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/422007/465888null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Ophthotech-sets-its-sights-on-AMD/ArticleStandard/Article/detail/457653?contextCategoryId=43931&ref=25 Ophthotech Corporation has announced deals with two companies to obtain the rights to treatments for age-related macular degeneration (AMD). 2007-09-17T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/382007/457653null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Urgent-need-for-new-AMD-drugs/ArticleStandard/Article/detail/457656?contextCategoryId=43931&ref=25 The decline in quality of life (Qol) and the increased need for daily living assistance in patients with wet age-related macular degeneration (AMD) substantiates the need for new treatments that can halt disease progression, according to a multi-country study published in the September issue of Archives of Ophthalmology. 2007-09-17T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/382007/457656null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/AMD-eye-drops-trial-kicks-off/ArticleStandard/Article/detail/455255?contextCategoryId=43931&ref=25 TareGen has initiated a multicentre Phase II clinical trial for the topically applied TG100801 in patients with age-related macular degeneration (AMD). 2007-09-07T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/362007/455255null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/C3-gene-linked-to-AMD/ArticleStandard/Article/detail/454894?contextCategoryId=43931&ref=25 The gene, complement C3, has been identified as playing an important role in the pathogenesis of age-related macular degeneration. 2007-09-06T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/362007/454894null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Stem-cell-project-to-cure-AMD-underway/ArticleStandard/Article/detail/451248?contextCategoryId=43931&ref=25 Researchers from University College London (UCL), Moorfields Eye Hospital and the University of Sheffield, UK are launching a pioneering project that plans to use stem cells to cure blindness resulting from age-related macular degeneration. 2007-08-22T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/342007/451248null HTML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Fusion-protein-anti-VEGF-agent-well-tolerated-for-/ArticleStandard/Article/detail/561005?contextCategoryId=43931&ref=25 Intravitreal injection of up to 4 mg of a fusion protein that is an anti-vascular endothelial growth factor agent (VEGF Trap-Eye, Regeneron Pharmaceuticals Inc.) is well tolerated and yields no evidence of ocular inflammation. The agent appears to produce rapid and durable clinical increases in best-corrected visual acuity, along with improvements in anatomic features, in patients with neovascular (wet) age-related macular degeneration. 2007-08-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/432008/561005null XML http://www.oteurope.com/ophthalmologytimeseurope/AMD+news/Pegaptanib-a-success-as-AMD-maintenance-therapy/ArticleStandard/Article/detail/561003?contextCategoryId=43931&ref=25 Interim results of a study of pegaptanib sodium as maintenance therapy for age-related macular degeneration show that patients previously treated successfully with other agents maintain visual and anatomic stability. 2007-08-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/432008/561003null XML http://www.oteurope.com/ophthalmologytimeseurope/Retina+clinical/NICE-decision-disappoints-AMD-sufferers-in-the-UK/ArticleStandard/Article/detail/449586?contextCategoryId=43931&ref=25 The National Institute for Health and Clinical Excellence (NICE) in England produced its first Appraisal Consultation Document (ACD) regarding the use of anti-vascular endothelial growth factor (anti-VEGF) drugs for the treatment of wet age-related macular degeneration (AMD) recently. Essentially, the document recommended that the new anti-VEGF inhibitor Lucentis (ranibizumab; Novartis Ophthalmics) may be used only to treat predominantly classic subfoveal choroidal neovascularization (CNV) which shows evidence of progression in the second affected eye, provided the visual acuity is between 6/12 and 6/96.1 After considering feedback from formal consultees, the Appraisal Committee will prepare a Final Assessment Document (FAD) for submission to NICE who will then issue guidance. 2007-07-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/332007/449586null XML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/AMD-eye-drop-enters-Phase-II/ArticleStandard/Article/detail/434443?contextCategoryId=43931&ref=25 CoMentis (formerly Athenagen) has initiated a Phase II trial of ATG3, a topical eye drop therapy for the treatment of neovascular age-related macular degeneration (AMD). 2007-06-14T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/242007/434443null HTML